CHINA PHARMA HOLDINGS, INC.
CHINA PHARMA HOLDINGS, INC. (CPHI): 42 pipeline candidates · 2 upcoming catalysts · ~39 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
39.0 months
D/E 0.22 · 0% dilution
Lead: Approved
42 candidates
2 upcoming, next in ~286d
N/A
A transparent, data-derived signal for CHINA PHARMA HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$31.8M
Cash
$168K
Quarterly Burn
$55K
Runway
39.0 mo
Revenue
$984K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (42 candidates)
| Drug | Phase |
|---|---|
| Alginic Sodium Diester Injection | Approved |
| androgen deprivation therapy | Phase 3 |
| Andrographolide | Approved |
| apg-2575 | Phase 1/Phase 2 |
| apg-5918 | Phase 1 |
| asc30 | Phase 2 |
| Bumetanide for Injection | Approved |
| Candesartan | Approved |
| Cefaclor Dispersible Tablets | Approved |
| Cefalexin Capsules | Approved |
Showing 10 of 42 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$15K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 12,924 | $8K |
| renaissance technologies llc | 11,418 | $7K |
| citigroup inc | 996 | $608 |
| danske bank a/s | 1 | $1 |
Frequently asked questions
How many drug candidates are in CHINA PHARMA HOLDINGS, INC.'s pipeline?
CHINA PHARMA HOLDINGS, INC. (CPHI) has 42 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CHINA PHARMA HOLDINGS, INC.'s lead drug candidate?
CHINA PHARMA HOLDINGS, INC.'s most advanced tracked candidate is Alginic Sodium Diester Injection (Approved) for Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease..
What is CHINA PHARMA HOLDINGS, INC.'s next catalyst?
CHINA PHARMA HOLDINGS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients" — expected March 31, 2027.
What is CHINA PHARMA HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CHINA PHARMA HOLDINGS, INC. has approximately 39.0 months of cash runway.
What is CHINA PHARMA HOLDINGS, INC.'s market capitalization?
CHINA PHARMA HOLDINGS, INC.'s market capitalization is approximately $31.8M.
Get the full picture on CHINA PHARMA HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.